Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0043167 (
pertussis
)
19,595
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In 1974, the authors reported the isolation and characterization of protective antigens of Bordetella
pertussis
in mice. With this information, an acellular
pertussis
vaccine was developed, composed mainly of
pertussis
toxin (PT) and filamentous haemagglutinin (FHA). Substances causing side effects, especially lipopoly sacahoride (LPS) or endotoxin that cause fever, were removed, and detoxification of the PT by
formaldehyde
with retention of potency was achieved. In 1981, an acellular
pertussis
vaccine called the "Adsorbed Purified
Pertussis
Vaccine" was approved in Japan, in place of the whole-cell
pertussis
vaccine. The acellular
pertussis
vaccine has been widely accepted as safer and more efficacious in Japan. Since 1981, intense surveillance has shown that there are only rare adverse reactions and that
pertussis
has virtually been eliminated in Japan. Evaluation of active immunization with highly purified and pharmacologically inert PT and FHA and passive immunization with polyclonal and monoclonal antibodies, provide quantitative data about the vaccine-induced immunity in mice. Finally, it was discovered that the PT toxoid in the vaccine is the major and essential protective antigen. The toxoid of PT should be sufficient for protection against
pertussis
.
...
PMID:Development of acellular pertussis vaccines. 1060 Jan 85
NAVA's acellular
pertussis
vaccine is based on highly purified
pertussis
toxin (PT) inactivated with H(2)O(2). PT was analysed using advanced biochemical methodology including mass spectroscopy (LC/MS), yielding mass and peptide mapping information on the subunits. Pertactin, adenylate cyclase, and Fim 1, 2 were below detection levels and only trace amounts of filamentous haemagglutinin (FHA) have been identified as a minor impurity. The vaccine does not induce anti-FHA antibodies during the course of a 3-dose primary immunization series in infants. B and T cell epitopes are preserved to a higher extent after H(2)O(2)detoxification when compared with chemical inactivation with
formaldehyde
, thus providing new information explaining why vaccines employing
formaldehyde
detoxified PT may need additional
pertussis
components added to induce high levels of protection. Anti-PT antibodies generated by NAVA diphtheria, tetanus, and acellular
pertussis
vaccine (DTaP) showed a positive correlation with protection against WHO-defined
pertussis
. The safety profiles for these vaccines showed low reactogenicity with no serious adverse events due to the vaccines.
...
PMID:DTaP vaccines from north american vaccine (NAVA): composition and critical parameters. 1060 Jan 91
Physico-chemical methods are being developed for use in the control and standardization of acellular
pertussis
vaccines and their individual components. We have compared native and detoxified preparations of the B.
pertussis
antigens,
pertussis
toxin (PT), filamentous haemagglutinin (FHA), and the 69-kDa outer membrane protein (P69) using circular dichroism (CD), fluorescence spectroscopy, SDS-PAGE and FPLC gel filtration chromatography. Upon aldehyde detoxification, PT underwent a large change in its intrinsic fluorescence maximum (8-10 nm red-shift) and a large increase in its apparent size, detected by chromatography. Polyacrylamide gels showed individual subunits of the same apparent molecular weight (M(r)) as well as some polypeptides of higher M(r). FHA also changed conformation (5-nm red-shift in intrinsic fluorescence) upon aldehyde detoxification, with a resultant increase in the M(r)of its major constituent. The P69 protein appeared quite robust to
formaldehyde
treatment as measured by the same methods. Its near-UV CD spectrum contains a prominent tryptophan band; so this method may be more suitable for observing differences in conformation. We also examined an aluminium-desorbed DTaP preparation by these methods. When used in conjunction with immunochemical and toxicological assays, these methods are informative and useful in the characterization of candidate standards and should be valuable methods for ensuring the consistency of manufactured vaccines.
...
PMID:Physico-chemical analysis of Bordetella pertussis antigens. 1060 Feb 5
The characterisation of an acellular
pertussis
vaccine composed of a genetically modified
pertussis
toxin, filamentous haemagglutinin and pertactin is described. The three antigens are submitted to a mild treatment with
formaldehyde
in the presence of lysine before their use in vaccine formulation. Characterisation is performed by amino acid analysis, SDS-PAGE, analytical size exclusion chromatography and, in the case of pertactin, isoelectrofocusing. The effect of some variables on pertactin
formaldehyde
treatment has been studied by means of isoelectrofocusing and mouse immunogenicity.
...
PMID:Physicochemical characterisation of the pertussis vaccine. 1121 35
A combination of spectroscopic and chromatographic methods has been used to monitor the quality and integrity of diphtheria,
pertussis
and tetanus toxoids (DTxd, PTxd and TTxd) which have been prepared from the toxins by
formaldehyde
treatment. Different processes for detoxifying all three toxins have yielded toxoids varying in their molecular size, including oligomers (associated monomers) and aggregates (high molecular weight complexes of non-specifically associated monomers). Changes in the intrinsic fluorescence spectra of the polypeptides have been observed in some sized fractions of DTxd and PTxd. Some physico-chemical changes have been observed to correlate with a loss of antigenicity. Spectroscopic and chromatographic methods are useful not only in monitoring the stability and consistency of vaccine starting materials, but can also be used to dissect heterogeneous toxoid preparations.
...
PMID:Monitoring of diphtheria, pertussis and tetanus toxoids by circular dichroism, fluorescence spectroscopy and size-exclusion chromatography. 1121 53
In an attempt to develop a safer
pertussis
vaccine, we successfully purified 3
pertussis
protective antigens-
pertussis
toxin, filamentous hemagglutinin, and a 69-kDa outer membrane protein (also named pertactin), from Bordetella
pertussis
strain ATCC 9340. The toxicity of
pertussis
toxin could be effectively reduced by the treatment with
formaldehyde
0.07% while preserving of a high degree of immunogenicity. By mixing purified
pertussis
antigens with diphtheria and tetanus toxoids (DT), we have formulated a DT acellular
pertussis
(DTaP) vaccine. Toxicity studies on body-weight gain in mouse, histamine sensitization, lymphocyte promoting, and Chinese hamster ovary cell clustering tests suggested that this DTaP vaccine is safer than a whole cell vaccine produced in France (DTP[F]). The formulated vaccine elicited high levels of anti-
pertussis
toxin antibodies in both mice and monkeys. In mice, a 2-fold neutralization of anti-
pertussis
toxin antibodies was produced by DTaP compared with DTP(F) vaccine and an acellular vaccine manufactured in Japan (DTaP[J]). More importantly, in intracerebral challenge assay in mouse, this vaccine also provided a better protection than DTaP(J).
...
PMID:Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin. 1182 3
Bordetella
pertussis
toxin (PTX), a key component of acellular
pertussis
vaccines, is known to be endowed with adjuvant properties. In experiments designed to get insights into the interactions between PTX and circulating immune cells, we first observed that addition of PTX to adult whole blood induced the release of IL-12 and TNF-alpha as well as maturation of myeloid dendritic cells (DC). These effects were still present with a toxin mutant devoid of ADP-ribosyltransferase activity but not with a
formaldehyde
-inactivated toxin. These findings indicate that cytokine production and DC maturation require the intact structure of PTX but not its enzymatic activity. Secondly, studies on DC generated in vitro by culturing monocytes with IL-4 and GM-CSF showed that PTX directly stimulates MHC class II and costimulatory molecules up-regulation, cytokine synthesis and NF-kappa B activation. Finally, comparison of data obtained in adult vs. cord blood revealed deficient responses of neonatal DC to PTX. These data suggest new applications of PTX and PTX mutants as vaccine adjuvants.
...
PMID:Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. 1238 32
A panel of
pertussis
toxin (PT) preparations with varying levels of residual toxicity was prepared by treatment of native PT with
formaldehyde
(0-1.00% (w/v)) with the purpose of investigating the effects of residual toxicity on immunogenicity. The catalytically inactive mutant PT (PT-9K/129G) was used for comparison. Results from in vitro ADP-ribosyl transferase and Chinese hamster ovary (CHO)-cell toxicity assays demonstrated a
formaldehyde
-dependent reduction in PT toxicity, and implied that both A and B domain functions of PT were modified. The in vivo histamine sensitisation and leukocyte proliferation tests suggested that the
formaldehyde
-treated native PT preparations were subject to reversion to toxicity. Reversion was confirmed by in vitro toxicity assays, which demonstrated recovery of A and B domain functions. The presence of high molecular weight aggregated and cross-linked species of PT in these preparations did not appear to be detrimental to the production of a neutralising antibody response. IgG responses to native and non-catalytic mutant PT suggested that low levels of residual activity in the native PT enhanced the antibody response, while higher levels of activity inhibited the response. Using the non-catalytic mutant PT showed that
formaldehyde
-induced changes were not detrimental to the magnitude of the PT-specific antibody response but did reduce the PT-specific neutralising activity. In conclusion, the residual toxicity of PT preparations following
formaldehyde
treatment may play an important role in the immune response to
pertussis
vaccine, potentially altering the quality, class and magnitude of the antibodies produced to PT.
...
PMID:Modifications of the catalytic and binding subunits of pertussis toxin by formaldehyde: effects on toxicity and immunogenicity. 1274 63
Pertussis
toxin (PT) is used in its
formaldehyde
-detoxified form in acellular
pertussis
vaccines for preventing whooping cough in children. The effects of
formaldehyde
treatment (up to 0.5% (w/v)
formaldehyde
) on the size, molecular association, folding and monoclonal antibody (mAb) binding of PT were studied to further define the structural nature of the high molecular weight species as related to their epitope integrity. Analytical ultracentrifugation (AUC) demonstrated that
formaldehyde
treatment of PT prevented the dissociation of the holotoxin. Together with results from size exclusion chromatography (SEC), SEC/multi-angle laser light scattering (MALLS) and immunoblotting it was demonstrated that PT increased in molecular weight and heterogeneity as a function of
formaldehyde
concentration, caused at least in part by covalent cross-linking. Five mAbs specific for PT subunits (S1-S5) bound to the cross-linked species, although there was some loss of epitopes in the larger aggregates. Intrinsic fluorescence spectroscopy gave evidence of progressive unfolding and re-association of PT. These findings demonstrate that a favourable balance between protein stabilisation and denaturation may be achieved by the treatment of
pertussis
toxin with
formaldehyde
, and provides a basis for determining the significance of high molecular weight cross-linked species of
pertussis
toxin in protection against whooping cough.
...
PMID:Novel configurations of high molecular weight species of the pertussis toxin vaccine component. 1274 5
Tetanus neurotoxin (TeNT),
pertussis
toxin (PT) and
pertussis
filamentous haemagglutinin (FHA) are major virulence factors of Clostridium tetani and Bordetella
pertussis
, which are the causative agents of tetanus and whooping cough respectively. Inactivated forms of these virulence factors are the protein components of vaccines against these diseases. Here we report microcalorimetric studies to characterize these proteins. The microcalorimetric titration curves of TeNT with micelles of gangliosides GD1b, GT1b and GQ1b were biphasic. For these gangliosides a high-affinity binding site (KD 45-277 nM) can be distinguished from a lower-affinity binding event (KD 666-1190 nM). This is direct evidence for multiple binding sites for gangliosides of the 1b series at TeNT as proposed by Emsley et al. [Emsley, Fotinou, Black, Fairweather, Charles, Watts, Hewitt and Isaacs (2000) J. Biol. Chem. 275, 8889-8894]. In agreement with previous reports, no binding was observed for gangliosides GM1, GM2, GM3 and GD2. The thermal denaturation of TeNT was characterized by two unfolding transitions centred around 57.4 and 62.4 degrees C. The conversion of TeNT into the toxoid form by
formaldehyde
treatment was accompanied by a large increase in Tm (the midpoint of protein unfolding transition, that is, the temperature at which half the protein is denatured and the other half is still present in its native form). Fetuin and asialofetuin bound to PT with similar affinities (KD 420 and 335 nM respectively). Binding was largely enthalpy-driven and counterbalanced by an unfavourable entropy change, indicating a loss of conformational flexibility. The latter could account for the observed inhibition of ATP binding after binding to fetuin. Furthermore, the molecular limits of mature PT subunit S5 were defined by MS and N-terminal peptide sequencing. The differential-scanning-calorimetry thermogram of FHA shows four well-resolved unfolding transitions, a finding consistent with the sequential denaturation of four structural domains.
...
PMID:The use of microcalorimetry to characterize tetanus neurotoxin, pertussis toxin and filamentous haemagglutinin. 1291 36
<< Previous
1
2
3
4
5
Next >>